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As human society ages globally, age-related disorders are becom-
ing increasingly common. Due to decreasing physiological reserves
and increasing organ system dysfunction associated with age,
frailty affects many elderly people, compromising their ability to
cope with acute stressors. Frail elderly people commonly manifest
complex clinical symptoms, including cognitive dysfunction, hypo-
mobility, and impaired daily activity, the metabolic basis of which
remains poorly understood. We applied untargeted, comprehen-
sive LC-MS metabolomic analysis to human blood from 19 frail and
nonfrail elderly patients who were clinically evaluated using the
Edmonton Frail Scale, the MoCA-J for cognition, and the TUG for
mobility. Among 131 metabolites assayed, we identified 22
markers for frailty, cognition, and hypomobility, most of which
were abundant in blood. Frailty markers included 5 of 6 markers
specifically related to cognition and 6 of 12 markers associated
with hypomobility. These overlapping sets of markers included
metabolites related to antioxidation, muscle or nitrogen metabo-
lism, and amino acids, most of which are decreased in frail elderly
people. Five frailty-related metabolites that decreased—1,5-anhy-
droglucitol, acetyl-carnosine, ophthalmic acid, leucine, and isoleu-
cine—have been previously reported as markers of aging,
providing a metabolic link between human aging and frailty.
Our findings clearly indicate that metabolite profiles efficiently
distinguish frailty from nonfrailty. Importantly, the antioxidant
ergothioneine, which decreases in frailty, is neuroprotective. Oxi-
dative stress resulting from diminished antioxidant levels could be
a key vulnerability for the pathogenesis of frailty, exacerbating
illnesses related to human aging.
frailty | antioxidants | cognitive impairment | metabolomics | aging marker
Human society is aging globally, in developed as well as indeveloping countries, and people over age 85 now constitute
1.6% of the world population. While life expectancy is in-
creasing, there is also an alarming rise in the number of frail
people who are predisposed to be bedridden and to require
nursing care. The prevalence of frailty among those aged 65 and
over is estimated at 17%, or approximately 120 million individ-
uals worldwide (1). Frail people suffer not only from physical
disabilities, but also from psychophysiological and social prob-
lems (2), and thus require more social resources than healthy
peers. Frailty compromises their ability to cope with acute
stressors due to declining physiological reserves and organ sys-
tem function (2, 3), although it has been suggested that frailty
may be reversible (4). Moreover, human aging is a highly com-
plex biological process exhibiting great individual variation, and
until now, its metabolic basis has been little understood.
Because all tissues and organs are supplied by the circulatory
system, blood should reflect environmental conditions, genetic
and epigenetic factors, nutritional status, exposure to exogenous
substances, and lifestyle factors (5, 6). Therefore, human blood
samples are expected to document not only individual genetic
variability, but also differences in physiological responses and
homeostatic mechanisms. For example, recent studies suggest
that in circulating leukocytes, telomere length (a biomarker of
aging) is affected not only by age, but also by disease, psycho-
physiological condition, and lifestyle (7, 8).
Metabolomics, a tool for evaluating metabolite profiles, em-
ploys liquid chromatography–mass spectrometry (LC-MS) to
reveal complex but highly integrated biological processes (5).
Although noncellular components (serum or plasma) of blood
have most often been used for metabolomic assays (5), we de-
veloped whole blood and red blood cell metabolomics (9) to
comprehensively investigate metabolic foundations of human
aging. Metabolomic analyses enable us to detect metabolites
related to amino acid metabolism, the tricarboxylic acid (TCA)
cycle, nitrogen, sugar, purine/pyrimidine, lipid metabolism,
antioxidation, energy supply, and diet.
Based on these quantitative, reproducible analytical methods,
we recently reported 14 age-related metabolites relevant to
antioxidative defense and nitrogen metabolism (10). Four recent
reports drew divergent, nonoverlapping conclusions (11–14),
stemming from different experimental designs. For example, the
former two reports applied the Fried CHS index as a diagnostic
tool, efficiently detecting hypomobility but offering no cognitive
assessment (2), while the latter two used a 70-item clinical Frailty
Index focusing mainly on activities of daily living (ADL) as-
sessment (15). Here we report the untargeted metabolomic
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analysis of blood from frail and nonfrail elderly people. For
frailty diagnosis, we applied the Edmonton Frail Scale (EFS) and
the Japanese version of the Montreal Cognitive Assessment
(MoCA-J) to evaluate cognitive aspects of frailty (16, 17). We
show that antioxidants, amino acids, and metabolites related to
muscle or nitrogen metabolism link frailty to cognitive impairment
and hypomobility.
Results and Discussion
Nineteen elderly participants, including 7 males and 12 females
with a mean age of 84.2 ± 6.9 y, were examined using the EFS,
the MoCA-J for cognitive function (17, 18), and the Timed Up &
Go (TUG) test for motor ability (19) (Fig. 1A). The EFS is an
efficient diagnostic tool, comprising 10 questions to assess cog-
nitive ability (clock-drawing test), mobility (TUG test), and
fundamental daily activity, in which a score ≥7 indicates frailty
(on a scale of 0 to 17) (16). It also covers domains related to
health status, functional independence, social support, medica-
tions, nutrition, mood, continence, and illness burden. The
MoCA-J evaluates short-term memory, visuospatial ability, var-
ious executive functions, attention, concentration, working
memory, language, and temporal and spatial orientation. An
MoCA-J score below a threshold of 25 to 26 (out of 30) indicates
mild cognitive impairment (10). Clinical attributes of the study
participants are summarized in SI Appendix, Table S1.
First, we clinically evaluated whether the 19 participants were
frail, cognitively impaired, or hypomobile, according to EFS,
MoCA-J, and TUG scores. Nine individuals (average age, 88.2 ±
6.8 y) were diagnosed as frail (average EFS, 9.0 ± 1.2), while 10
(average age, 80.5 ± 4.7 y) were not (average EFS, 4.7 ± 1.1) (SI
Appendix, Table S1). According to the MoCA-J assessment, 15
individuals displayed impaired cognition (average score; 19.3 ±
3.8), while 4 were normal (average 27.0 ± 0.8). Regarding mo-
bility, 12 participants exhibited a prolonged TUG test (>10 s),
while 7 were normal (SI Appendix, Table S1). Both the MoCA-J
and TUG results were significantly diminished in frailty (Fig. 1B
and SI Appendix, Table S1). Significant correlations of EFS with
MoCA-J, TUG, and functional independence test results
(Fig. 1C and SI Appendix, Fig. S1) confirm that frailty involves
simultaneously deteriorating physiological functions and social
activities.
In this context, we performed untargeted analysis of 131
compounds in whole blood (Dataset S1). Our comprehensive
comparison of these metabolites between frail and nonfrail el-
derly identified 15 compounds as frailty markers (Fig. 1D and SI
Appendix, Table S2). In addition, we found that 6 metabolites
Fig. 1. Metabolomic study of frailty. (A) Diagram of the study protocol. All participants were clinically examined, and their blood was analyzed using
untargeted comprehensive metabolomics. (B) Comparison of MoCA-J and TUG test results between frail and nonfrail subjects. **P < 0.01. Error bars represent
mean ± SD. (C) Pearson’s correlation of the linear model between EFS and MoCA-J (Left) or TUG (Right). (D) Overview of identified metabolites related to EFS,
MoCA-J, and TUG.
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involved in cognitive impairment and 12 metabolites related to
low mobility were also significantly changed (Fig. 1D).
Among the 15 frailty markers, 13 compounds—acetyl-carnosine,
ergothioneine (ET), S-methyl-ergothioneine (S-methyl-ET), trimethyl-
histidine (hercynine), ophthalmic acid (OA), 2-ketobutyrate,
urate, 1,5-anhydroglucitol (1,5-AG), proline, isoleucine, leucine,
tryptophan, and methionine—decreased in frailty, while two metab-
olites enriched in red blood cells—creatine and UDP-glucuronate—
increased. Ten of 15 frailty markers showed correlations with EFS
scores (SI Appendix, Table S2). Based on the MoCA-J, a comparison
of cognitively impaired subjects and controls detected significant
changes in six metabolites—acetyl-carnosine, ET, tryptophan,
creatine, UDP-glucuronate, and UDP-glucose—all of which except
UDP-glucose were also frailty markers (Fig. 1D and SI Appendix,
Table S3). Among these six metabolites, three compounds—tryptophan,
creatine, and UDP-glucuronate—displayed correlations with the
MoCA-J results (SI Appendix, Table S3). Thus, Pearson’s cor-
relation of these marker metabolites also disclosed their con-
gruence with relevant clinical attributes (SI Appendix, Fig. S2).
We previously reported 14 aging-related markers (10). In the
present study, we noticed that five frailty-related metabolites that
were decreased—acetyl-carnosine, OA, isoleucine, leucine, and
1,5-AG—were also among these aging markers (Fig. 2 and SI
Appendix, Fig. S3A), insinuating a metabolic connection between
frailty and human aging.
Strikingly, among 15 frailty markers, 7 compounds that were
decreased are relevant to antioxidative defense: acetyl-carnosine,
ET, S-methyl-ET, trimethyl-histidine, OA, 2-ketobutyrate, and
urate (Fig. 2A). Trimethyl-histidine and S-methyl-ET are in-
volved in ET synthesis, mainly in mushrooms and other fungi
(20). OA is a tripeptide analog of glutathione (21), the precursor
of which is 2-ketobutyrate. Thus, the ergothioneine and OA
pathways are greatly affected in frailty. Acetyl-carnosine, formed
from β-alanine and histidine, is enriched in muscle (22). Urate is
one of the most abundant antioxidants in blood (23). Four of
these seven antioxidants are also associated with cognitive im-
pairment or low mobility: acetyl-carnosine, ET, OA, and
2-ketobutyrate (Fig. 2A).
We observed significant decreases in five amino acids—me-
thionine, proline, tryptophan, isoleucine, and leucine—in the
frail subjects, while tryptophan, methionine, and proline were
also reduced in patients manifesting cognitive impairment or low
mobility (Fig. 2B). Tryptophan is a precursor for the neuro-
transmitters serotonin and dopamine and is involved in kynur-
enine metabolism in muscle (24), while leucine and isoleucine
are essential for maintaining muscle strength. According to
Pearson’s correlation analysis, among the 15 metabolites asso-
ciated with frailty (Fig. 3A), five amino acids showed close cor-
relations with several antioxidative metabolites. Correlation
coefficients of acetyl-carnosine with methionine and proline
were r = 0.50 and 0.61, respectively, while those of S-methyl-ET
with methionine, proline, tryptophan, isoleucine, and leucine
were r = 0.52 to 0.65 (Fig. 3 A and B). Interestingly, methionine,
proline, and tryptophan, the three amino acids that were de-
creased in frailty, have been reported as radical scavengers
in vitro (25, 26), consistent with recent findings in proteomic
analysis (27). Thus, antioxidative defense is greatly impaired
in frailty.
Twelve metabolites were identified as hypomobility markers
(Fig. 3C and SI Appendix, Fig. S2B and Table S4), some of which
are also frailty markers (acetyl-carnosine, OA, 2-ketobutyrate,
methionine, proline, and UDP-glucuronate) and cognitive markers
(acetyl-carnosine and UDP-glucuronate) (Figs. 2 and 3D). Acetyl-
carnosine and UDP-glucuronate are linked to increased frailty and
to decreased cognition and mobility. The other six hypomobility
markers include five decreased metabolites—N3-methyl-histidine,
isovaleryl-carnitine, arginine, hippurate, and adenine (Fig. 3C and
SI Appendix, Fig. S3B)—and increasedN-acetyl-aspartate (Fig. 3D).
Pearson’s correlation analysis revealed a close relationship of TUG
results with three metabolites: isovaleryl-carnitine, adenine, and
UDP-glucuronate) (SI Appendix, Table S4). N3-methyl-histidine is
an indicator of muscle deterioration (28), while isovaleryl-carnitine,
enriched in muscle, supplies acetyl-CoA to mitochondria. Hippu-
rate, synthesized in liver mitochondria from metabolized poly-
phenol, is involved in nitrogen metabolism (29). Arginine is also
utilized in the urea cycle. These four hypomobility metabolites are
involved in muscle or nitrogen metabolism, in addition to the in-
volvement of three muscle-related amino acids—tryptophan, iso-
leucine, and leucine—in frailty (Figs. 2B and 3C).
Women are at an intrinsic increased risk of frailty by virtue of
lower lean mass and strength compared with age-matched men
(2). There were significant differences in the skeletal muscle
mass index between males and females in our cohort (average,
7.49 vs 5.31; P = 0.00003), while metabolites related to muscle
mass include compounds involved in nitrogen metabolism (30).
Such compounds could be affected in sarcopenic frailty, with an
inherent risk in women.
In addition to increased N-acetyl-aspartate in hypomobility,
three up-regulated metabolites were identified: creatine and
UDP-glucuronate for frailty and UDP-glucose for cognition
(Fig. 3D). Creatine, which is increased in cognitive impairment
and frailty, serves as major energy storage in brain and muscle
(31). Creatine supplementation is effective for strengthening
muscle in athletes (32) and for treating some types of genetic
mental retardation associated with cerebral creatine deficiency
(33). Increased creatine might compensate for brain and muscle
dysfunction in frailty. Moreover, metabolites in UDP-glucuronate
biosynthesis are much up-regulated. UDP-glucuronate is involved
in the synthesis of ascorbic acid, formation of polysaccharides, and
detoxification (34, 35). UDP-glucuronate is increased in frailty,
cognitive impairment, and low mobility, and UDP-glucose is up-
regulated in cognitive impairment (Fig. 3D). It is noteworthy that
the antioxidant ET displays significant negative correlations with
creatine and UDP glucuronate (Pearson’s r = −0.76 and −0.56,
respectively) (Fig. 3A and SI Appendix, Fig. S4). It is possible that
increased creatine or UDP-glucuronate compensates for decreased
antioxidative defense in frailty, which would make frailty reversible.
Oxidative damage has been proposed to have a substantial impact
both on organismal aging in experimental models (36) and in ill-
nesses of aging, such as Alzheimer’s disease (37). As such, declining
antioxidative defense could be involved in the pathogenesis of
frailty, and oxidative stress may be a key vulnerability for frail
elderly people. While a total of 22 metabolites were identified
relative to frailty, cognitive impairment, and hypomobility,
levels of 16 compounds—acetyl-carnosine, ET, S-methyl-ET, OA,
urate, methionine, proline, tryptophan, isoluecine, leucine, 1,5-AG,
creatine, N3-methyl-histidine, isovaleryl-carnitine, hippurate, and
UDP-glucose—are abundant or moderately present in blood
(Fig. 4A), suggesting a possible involvement in pathogenesis.
Among the 22 metabolites that we identified as relevant to
frailty, cognitive /impairment, and hypomobility (Fig. 4A), partly
overlapping but distinct metabolite profiles support the notion
that frailty is an integrated spectrum of age-related disorders.
We addressed the question whether these metabolites are useful
for diagnosis of frailty. Heatmap comparisons indicated distinct
distributions of 15 frailty markers between frail and nonfrail
groups (Fig. 4B). Similar results were observed among 6 me-
tabolites for cognitive impairment and among 12 metabolites for
low mobility (Fig. 4B).
Next, we applied principal component analysis (PCA) based
on 10 metabolites related to EFS, MoCA-J, and TUG: acetyl-
carnosine, ET, OA, methionine, proline, tryptophan, N3-methyl-
histidine, creatine, UDP-glucuronate, and UDP-glucose. PCA
clearly distinguished frail elderly people from healthy counter-
parts (Fig. 4C). Interestingly, nonfrail people with cognitive im-
pairment or hypomobility were also separated from the frail and











healthy groups. Analysis of a correlation network between EFS
and 131 metabolites using Cytoscape 3.7.2 (38, 39) identified 17
metabolites significantly correlated with EFS, including 10 frailty
markers (SI Appendix, Table S2). Our metabolomic dissection of
frailty markers suggests an involvement of antioxidation in cog-
nition and an involvement of nitrogen metabolism in mobility.
These findings enhance our understanding of the pathogenesis of
frailty and offer hope for interventions to maintain normal
physiological levels of these metabolites.
Materials and Methods
Clinical Assessment. All clinical data were collected at Kyoto University
Hospital. Patients who were bedridden or who had kidney dysfunction (se-
rum creatinine >2.0 mg/dL) or liver damage (serum aspartate aminotrans-
ferase and alanine aminotransferase >50 U/L), were excluded from the
study. Clinical interviews, physical examinations, and blood tests were per-
formed for 19 elderly participants. The EFS is an efficient diagnostic tool
comprising 10 domains to assess cognitive ability (the clock-drawing test),
mobility (TUG test), and fundamental daily activity by questionnaire, in
which a score ≥7 indicates frailty (range, 0 to 17) (16). The EFS elicits in-
formation on functional independence, including meal preparation, shop-
ping, transportation, telephone use, housekeeping, laundry, money
management, and medications. In the TUG test, the time it takes to stand up
from a chair, walk normally to a point 3 m away, and return to sitting is
measured (19). In the EFS, a TUG test cutoff score of >10 s is classified as
hypomobility.
The MoCA-J evaluates short-term memory, visuospatial ability, various
executive functions, attention, concentration, working memory, language,
and temporal and spatial orientation. An MoCA-J score below a threshold of
25 to 26 (out of 30) is considered to indicate mild cognitive impairment
(17, 18).
Blood Sample Preparation for Metabolomic Analysis. Preparation of human
blood samples for metabolomic analysis has been described previously (9, 10,
40). In the morning, blood for clinical tests and metabolomic analysis was
drawn at the laboratory of Kyoto University Hospital. Until the time of blood
sampling, all participants were requested not to have breakfast to ensure
overnight fasting at least for 12 h, although they were allowed to spend
their time normally and to drink beverages without calories. Since some
metabolites are labile, blood samples were quickly quenched at −40 °C in
methanol to ensure quick sample processing. Then 10 nmol Hepes and Pipes
were added to each sample to serve as internal standards.
LC-MS Conditions. Untargeted, comprehensive analysis by LC-MS was carried
out as described previously (9, 10, 40). LC-MS data were obtained using an
Ultimate 3000 DGP-3600RS liquid chromatograph and an LTQ Orbitrap mass
spectrometer (Thermo Fisher Scientific). LC separation was done using a ZIC-
pHILIC column (Merck SeQuant; 150 mm × 2.1 mm, 5 μm particle size). The
mobile phase was composed of ammonium carbonate buffer (10 mM, pH
9.3) and acetonitrile. Gradient elution from 80 to 20% acetonitrile over
Fig. 2. Antioxidants and amino acids were significantly decreased in frailty. (A) Seven antioxidants were identified as frailty markers: acetyl-carnosine, ET,
S-methyl-ET, trimethyl-histidine, ophthalmic acid, 2-ketobutyrate, and urate. Decreased antioxidants were also observed in cognitive impairment and
hypomobility. (B) Five amino acids were decreased in frailty: isoleucine, leucine, methionine, tryptophan, and proline. Tryptophan was also decreased in
cognitive impairment, while methionine and proline were also decreased in hypomobility. *P < 0.05. Error bars represent mean ± SD.
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30 min at a flow rate of 100 μL/min was used. An electrospray ionization (ESI)
source was used for MS detection. An injection of 1 μL was performed twice
for each sample, once with the ESI in positive ionization mode and once with
the ESI in negative mode. Spray was set to 4.0 kV for positive ESI and 2.8 kV
for negative ESI, while the capillary was adjusted to 350 or 300 °C. Nitrogen
gas was used as a carrier. The mass spectrometer was operated in full
scanning mode with a 100 to 1,000 m/z range and with MS/MS fragmenta-
tion scanning in an automatic data-dependent manner.
LC-MS Data Processing and Analysis. MZmine 2 (version 2.29) software (http://
mzmine.github.io) was used to measure peak areas for metabolites (41).
Isotopic peaks were eliminated. Lists of peaks for individual samples were
aligned according to their retention times and corresponding m/z values. A
total of 131 nonselective metabolites were identified for each sample by
comparing retention times and m/z values of peaks with those of standards
(Dataset S1) (9, 10, 40). If no standard compound was available, metabolites
were identified by the analysis of MS/MS spectra. Then all data acquired
were transferred into a spreadsheet, followed by analysis with R statistical
software (http://www.r-project.org). Statistical analysis included Student’s t test
to confirm significant differences between groups (with statistical significance
set at P < 0.05) and 95% confidence intervals, the ordinary least squares method
to confirm linear regression, and Pearson’s correlation to confirm relationships
between metabolites and clinical data (assuming P < 0.05). PCA was used to
visualize the metabolomic model. A correlation network involving EFS and 131
metabolites was analyzed using Cytoscape 3.7.2 (38) with Metscape (39).
Data Availability. Raw LC-MS data in mzML format are available from the
MetaboLights repository, http://www.ebi.ac.uk/metabolights/ (accession no.
MTBLS1540).
Ethics Statement. All participants signed informed consent forms prior to
examination, in accordance with the Declaration of Helsinki. Experiments
were carried out in agreement with relevant rules and official guidelines in
Japan. Approval for study protocols was given both by the Human Research
Ethics Committee of Kyoto University and by the Review Committee on
Human Subjects Research at Okinawa Institute of Science and Technology.
Fig. 3. Compounds relevant to muscle or nitrogen metabolism were decreased in hypomobility, while creatine and UDP-glucuronate were increased in
frailty. (A) Pearson’s correlation analysis for 15 frailty markers. Positive and negative correlations are shown in red and blue, respectively. (B) Statistical analysis
of the correlation between antioxidants and amino acids, acetyl-carnosine and proline (Upper) and S-methyl-ET and methionine (Lower). (C) Compounds
involved in muscle or nitrogen metabolism declined in the low mobility group, including N3-methyl-histidine, isovaleryl-carnitine, arginine, and hippurate. (D)
Four metabolites increased in frailty, cognitive impairment, or hypomobility. *P < 0.05; **P < 0.01. Error bars represent mean ± SD.
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